| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 4.23 | 0.05 (+1.20%) | 1.60 - 5.22 | 31.3 thousand (Below Avg) |
Market data as of 3:59PM 05/23/13. Quotes are delayed by at least 15 min.
| Open | 4.10 |
|---|---|
| Previous Close | 4.18 |
| Day's Range | 4.10 - 4.40 |
| Market Cap | 68.7M |
| Avg Volume (10 Day) | 47.7K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.09 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders -- New Phone Number for Audio Portion of Presentation
PR Newswire - Thursday 05/23/2013 9:16 AM ET
Galectin Therapeutics to Hold Conference Call to Provide Update Following Company's Annual Meeting of Shareholders
PR Newswire - Wednesday 05/15/2013 8:00 AM ET
Galectin Therapeutics Reports First Quarter 2013 Financial Results
PR Newswire - Friday 05/10/2013 4:00 PM ET
Galectin Inhibitors Reverse Liver Cirrhosis in Preclinical Studies
PR Newswire - Monday 04/29/2013 8:00 AM ET
| GALT | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|---|---|
| Catalyst Pharmaceutical Partners Inc | 0.84 | -1.72% |
| Supernus Pharmaceuticals Inc | 6.65 | +0.76% |
| Hi-Tech Pharmacal Co Inc | 34.38 | +1.69% |
| Avanir Pharmaceuticals Inc | 3.40 | +4.62% |
| Sagent Pharmaceuticals Inc | 17.86 | -0.53% |
Data is delayed by at least 15 min.